Non-small cell lung cancer
Not recruitingStudy of Sitravatinib and Nivolumab vs. Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Chemotherapy and Checkpoint Inhibitor Therapy
Study of Sitravatinib and Nivolumab vs. Docetaxel for Patients with Advanced Non-Small Cell Lung Cancer After Chemotherapy and Checkpoint Inhibitor Therapy
- Disease:Non-small cell lung cancer
- Substances:DocetaxelNivolumab+1
The Netherlands- Participants:18–64 years · 65+ years
- Substances:Docetaxel
- Sponsor:Mirati Therapeutics Inc.











